

2nd NEWSLETTER IMMUNOSEP STUDY

Dear Investigators,


We send you our 2nd Newsletter to keep you updated with the progress of the ImmunoSep trial

Current progress (until December 3rd 2022):

- 22 sites activated
- 286 patients screened
- 108 patients randomized

Our final Goal: 280 patients randomized by April 2023

MONTHLY PROGRESS



MALS: macrophage activation-like syndrome



SITE PROGRESS

Study site (according to entries at sepsisonline.org)	# Screened	# Enrolled
Study site (according to entires at sepsisoninie.org)	subjects	Subjects
Intensive Care Unit, "Ippokrateion" Thessaloniki General Hospital	66	33
Intensive Care Unit, "AHEPA" Thessaloniki University General Hospital	38	11
4th Department of Internal Medicine, ATTIKON University Hospital, Athens	36	11
Intensive Care Unit, "Theageneio" Thessaloniki Anticancer Hospital	20	5
Intensive Care Unit, "KAT" General Hospital of Attika, Athens	18	10
2 nd Department of Critical Care Medicine, ATTIKON University Hospital, Athens	17	13
Intensive Care Unit, "Aghios Dimitrios" Thessaloniki General Hospital	17	4
Multipurpose Intensive Care Unit, SOTIRIA General Hospital of Chest Diseases of Athens, Athens	16	9
Latsio Intensive Care Unit, "Thriasio" Elefsis General Hospital	12	3
Intensive Care Unit, "G.Gennimatas" Thessaloniki General Hospital	10	1
Department of Internal Medicine and Infectious Diseases, Amsterdam Medical Centre	8	0
Intensive Care Unit University Medical Center Radboud, Nijmegen	8	2
Intensive Care Unit, Alexandroupolis University General Hospital	7	1
Intensive Care Unit, Ioannina University General Hospital	3	1
2 nd Department of Propaedeutic Internal Medicine, ATTIKON University Hospital, Athens	3	1
Department of Internal Medicine, Larissa University General Hospital	2	1
Intensive Care Unit General Hospital Asklepieio Voulas	2	0
Intensive Care Unit, "Koutlimbaneio & Triantafylleio" Larissa General Hospital	1	1
Intensive Care Unit, "Tzaneio" Piraeus General Hospital	1	1
1st Department of Pulmonary Medicine and Intensive Care Unit, SOTIRIA General	1	0
Hospital of Chest Diseases of Athens, Athens	0	
5 th Department of Internal Medicine, "Evangelismos" General Hospital of Athens	0	0
3 rd Department of Internal Medicine, SOTIRIA General Hospital of Chest Diseases of Athens, Athens	0	0
Department of Internal Medicine and Infectious Diseases, Centre Hospitaliaire Universitaire Vaudois, Lausanne	0	0
Intensive Care Unit, Jena University Hospital	0	0
Department of Internal Medicine and Infectious Diseases, Cluj-Napoca	0	0
Intensive Care Unit, General Hospital of Herakleio	0	0
TOTAL	286	108
<u>Sites to become soon activated</u>		
424 General Military Hospital, Intensive Care Unit, Thessaloniki		
Intensive Care Unit, General Hospital of Karditsa		
Intensive Care Unit, General Hospital of Chest Diseases of Athens, SOTIRIA		
1st Department of Internal Medicine, "Evangelismos" General Hospital of Athens		
Intensive Care Unit, General Hospital of Athens, Korgialenio - Benakio		
Intensive Care Unit and Lung Disease Clinic of Nursing School, General Oncology Center "Agii Anargiri"		



Congratulations to Our Pioneers for 2nd semester 2022

Centre	# Screened subjects	# Enrolment Subjects	
Intensive Care Unit, "Ippokrateion" Thessaloniki General	36	17	
Hospital (PI: Eleni Mouloudi, MD)	30	1,	
Intensive Care Unit, "AHEPA" Thessaloniki University General	24	7	
Hospital (PI: Eleni Gkeka, MD)	24		
4th Department of Internal Medicine, ATTIKON University	11	5	
Hospital, Athens (PI: Prof. Antonios Papadopoulos, MD, PhD)	11		
Multipurpose Intensive Care Unit, SOTIRIA General Hospital	11	4	
of Chest Diseases of Athens, Athens (PI: Maria Daganou, MD)	11	4	
Intensive Care Unit, Alexandroupolis University General	c	1	
Hospital (PI: Director of NHS Vassiliki Theodorou, MD)	6	<u> </u>	

Useful tips to remember

INCLUSION CRITERIA

- Both COVID-19 and non-COVID-19 may be enrolled
- COVID-19 Patients <u>without</u> secondary VAP/HAP/BSI are enrolled ONLY if they have **MALS**
- COVID-19 Patients with secondary VAP/HAP/BSI

Useful tips to remember

- 10-day dexamethasone course does NOT exclude the patient
- Treatments with Tocilizumab, Anakinra and Baricitinib do NOT exclude the patient

BSI: bloodstream infection CAP: community-acquired pneumonia HAP: hospital-acquired pneumonia MALS: macrophage activation-like

Please continue to update the eCRF daily and *especially* the field of SOFA as it is a part of primary endpoint!

A warm thank you

To all Investigators and study team members for your contribution so far! We appreciate your continued commitment to this study!

We congratulate the Intensive Care Unit of Radboud for enrolling their second patient